MetaCap

Hyperfine (HYPR) vs Outset Medical (OM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Outset Medical (OM) has outperformed Hyperfine (HYPR) over the past year, losing 34.5% versus a loss of 48.0%. Over five years, HYPR leads with a -94.5% price change compared with -99.6% for OM. Hyperfine is the larger company by market cap ($58.0 million vs $53.0 million), about 1.1 times the size.

Outset Medical converts more of its revenue into profit, with a net margin of -68.3% versus -262.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HYPR-47.95%OM-34.50%
+85%+14%-56%
Nov 21, 20251 yearNov 20, 2026
HYPR-94.51%OM-99.62%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HYPR versus OM key metrics
MetricHYPROM
Share price$0.5465$2.81
Market cap$57.96M$53.03M
1-day change+4.27%-3.44%
YTD return-44.18%-24.26%
1-year return-47.95%-34.50%
5-year return-94.45%-99.61%
EPS (TTM)$-0.29$-3.78
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.56M$119.48M
Revenue growth (YoY)+5.22%+5.09%
Net income (latest FY)$-35.57M$-81.65M
Gross margin49.79%39.13%
Operating margin-273.43%-55.83%
Net margin-262.29%-68.34%
52-week high$1.94$6.49
52-week low$0.488$2.77
Distance from 52-week high-71.76%-56.70%
Analyst consensusnonebuy
Avg. price target upside+271.45%+172.95%
Average volume760.76K140.40K
Shares outstanding90.99M18.87M
Employees102310
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • OM has outperformed HYPR by 13.5 percentage points over the past year.
  • Outset Medical is more profitable, keeping -68.3 cents of every revenue dollar as net income versus -262.3 cents for Hyperfine.

About Hyperfine

HYPR stock →

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees

About Outset Medical

OM stock →

Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 310 employees

HYPR vs OM FAQ

Which is bigger, Hyperfine or Outset Medical?

Hyperfine (HYPR) is larger, with a market capitalization of $57.96M compared with $53.03M for Outset Medical (OM).

Which stock has performed better over the past year, HYPR or OM?

OM returned -34.50% over the past 12 months, compared with -47.95% for HYPR (price return, excluding dividends). Past performance does not predict future results.

Are Hyperfine and Outset Medical in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons